Physician profile
Kenneth E Matthews
NPI 1013957612
$573.35
in general payments reported to CMS, 2019-2025
11 companies · $143 in 2025
The $143 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.75 · 2020: $14.40 · 2021: $43.55 · 2022: $21.41 · 2023: $113 · 2024: $146 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $151.35 | 2023-2024 | Jornay Pm |
| Pfizer INC. | $106.63 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.77 | 2019-2021 | |
| Tris Pharma INC | $43.69 | 2025 | Onyda Xr, Dyanavel Xr |
| Corium, LLC | $43.61 | 2023-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $40.77 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $30.45 | 2020-2025 | Rotateq, Vaxelis, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $26.55 | 2023 | |
| Supernus Pharmaceuticals, INC. | $18.68 | 2025 | Qelbree |
| Alk-Abello, INC | $18.34 | 2024 | Grastek, Odactra |
| Acadia Pharmaceuticals INC | $14.51 | 2024 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.